Benzinga · Sep 16, 2026
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $86
Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $79 to $86.
IR
NASDAQ · IRON
Disc Medicine, Inc.
Healthcare · Biotechnology
$56.65
Up+$0.91 (+1.63%)
Updated Oct 16, 2026, 8:57 AM
SID Score
3.3/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.53B
- P/E ratio
- -18.17
- Dividend yield
- 0.00%
- 52-week range
- $40.00 – $99.50
- Volume
- 699.76K
- Avg. volume
- 503.23K
Price performance · IRON
IRON price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 15, 2026
IRON closed at $56.65 after 21 trading sessions, down 18.11% for the selected period.
- Last close
- $56.65
- Period change
- -18.11%
- Period low
- $55.74
- Period high
- $69.53
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | $56.66 | $58.085 | $55.95 | $56.65 | 699.76K |
| Oct 14, 2026 | $56.21 | $58.835 | $55.48 | $55.74 | 430.72K |
| Oct 13, 2026 | $60.16 | $60.48 | $56.47 | $56.60 | 603.47K |
| Oct 12, 2026 | $62.20 | $62.76 | $60.355 | $60.48 | 657.22K |
| Oct 9, 2026 | $60.67 | $63.50 | $60.03 | $62.06 | 691.14K |
| Oct 8, 2026 | $60.71 | $61.58 | $58.22 | $60.77 | 846.82K |
| Oct 7, 2026 | $61.20 | $62.97 | $60.02 | $61.18 | 562.93K |
| Oct 6, 2026 | $63.70 | $64.66 | $61.31 | $61.65 | 1.42M |
| Oct 5, 2026 | $65.13 | $65.565 | $63.01 | $63.33 | 456.32K |
| Oct 2, 2026 | $64.56 | $66.55 | $63.81 | $64.51 | 684.73K |
| Oct 1, 2026 | $65.27 | $65.94 | $63.50 | $63.61 | 771.84K |
| Sep 30, 2026 | $66.08 | $66.08 | $64.24 | $65.46 | 671.49K |
| Sep 29, 2026 | $64.93 | $66.29 | $64.05 | $65.87 | 784.08K |
| Sep 28, 2026 | $64.83 | $66.255 | $63.96 | $64.92 | 480.55K |
| Sep 25, 2026 | $66.89 | $66.89 | $64.59 | $65.24 | 427.23K |
| Sep 24, 2026 | $66.09 | $66.58 | $64.31 | $66.44 | 455.57K |
| Sep 23, 2026 | $68.54 | $68.945 | $65.31 | $66.09 | 541.83K |
| Sep 22, 2026 | $69.65 | $69.79 | $67.68 | $68.48 | 450.84K |
| Sep 21, 2026 | $69.84 | $69.84 | $67.155 | $68.49 | 406.55K |
| Sep 18, 2026 | $69.13 | $69.60 | $67.705 | $69.53 | 1.08M |
| Sep 17, 2026 | $69.84 | $72.07 | $68.47 | $69.18 | 621.69K |
Latest IRON news
The latest Smart Investors Daily articles mentioning IRON.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IRON research
Overview
Company profile and research snapshot.
Company profile
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $123.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | Wells Fargo | Overweight | — |
| Sep 10, 2026 | Wedbush | Outperform | — |
| Sep 2, 2026 | Wedbush | Outperform | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 16, 2026 | Morgan Stanley | Overweight | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 14, 2026
Disc Medicine, Inc. (IRON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Disc Medicine, Inc. (IRON) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:45 AM EDTCompany ParticipantsJohn Quisel - CEO,...
Benzinga · Sep 10, 2026
Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones
Disc Medicine says Phase 2 RESTORE-PV data shows DISC-3405 reduces phlebotomy needs and controls hematocrit in polycythemia vera patients.
Benzinga · Sep 10, 2026
Wedbush Reiterates Outperform on Disc Medicine, Maintains $100 Price Target
Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and maintains $100 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
